CEEON HEPARIN SURFACE MODIFIED (ASM) ULTRAVIOLET LIGHT.

FDA Premarket Approval P960034

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for lens models with the heparin surface modification applied to all your single-piece pmma lenses approved in p810055. These models will be specified with a "c" following the number designation for the corresponding non-hsm pmma model. The lenses will be marketed under the trade name ceeon(tm) hsm pmma iols. This device is indicated for primary implantation for the visual correction of aphakia in adults in whom a cataractous lens has been removed by an extracapsular cataract extraction (ecce) or phacoemulsification. They are intended to be placed in the capsular bag.

DeviceCEEON HEPARIN SURFACE MODIFIED (ASM) ULTRAVIOLET LIGHT.
ApplicantABBOTT MEDICAL OPTICS INC
Date Received1996-10-01
Decision Date1998-08-12
Notice Date1998-10-27
PMAP960034
SupplementS
Docket Number98M-0725
Advisory CommitteeNeurology
Expedited ReviewNo
Combination Product No
Applicant Address ABBOTT MEDICAL OPTICS INC 1700 E. St. Andrew Place santa Ana, CA 92705

Supplemental Filings

Supplement NumberDateSupplement Type
P960034Original Filing
S002 2007-04-12 30-day Notice
S001 1999-12-20 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.